VitiligoWeb.com
I have reported on Clinuvel and their experimental drug Scenesse in the past. It looks like they are getting the go ahead in the US to enter a phase 3 study.
Scenesse is a photoreceptive drug. From the article, "Scenesse is a subdermal injectable designed to mimic the body's natural ability to create skin treatment melanin. It is being developed to treat EPP as well as vitiligo. Its INN designation is afamelanotide."
Melanin is what is lacking in skin with vitiligo when it loses color. There aren't many drugs in the pipeline for vitiligo, so hopefully the study will have positive results!
The company now expects to commence the trial in May. The randomised, double blind, placebo-controlled study will involve some 75 patients in up to seven centres. Patients will receive three Scenesse or placebo implants over a the six-month trial period.
To view the entire article, click below:
http://www.lifescientist.com.au/article/420686/clinuvel_set_accelerate_phase_iii_study_scenesse/
--------
No comments:
Post a Comment